Literature DB >> 31595227

The genetic risk of second cancers: should the therapy for acute lymphoblastic leukemia be individualized according to germline genetic makeup?

Kathleen E A Felton1, Christopher C Porter2, Jun J Yang3.   

Abstract

Entities:  

Keywords:  TP53; acute lymphoblastic leukemia; germline genetics; second cancers; treatment individualization

Year:  2018        PMID： 31595227      PMCID： PMC6782060          DOI： 10.1080/23808993.2018.1517026

Source DB:  PubMed          Journal:  Expert Rev Precis Med Drug Dev        ISSN： 2380-8993


× No keyword cloud information.
  21 in total

1.  Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.

Authors:  Phuong L Mai; Ana F Best; June A Peters; Rosamma M DeCastro; Payal P Khincha; Jennifer T Loud; Renée C Bremer; Philip S Rosenberg; Sharon A Savage
Journal:  Cancer       Date:  2016-08-06       Impact factor: 6.860

2.  Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy.

Authors:  Jop C Teepen; Flora E van Leeuwen; Wim J Tissing; Eline van Dulmen-den Broeder; Marry M van den Heuvel-Eibrink; Helena J van der Pal; Jacqueline J Loonen; Dorine Bresters; Birgitta Versluys; Sebastian J C M M Neggers; Monique W M Jaspers; Michael Hauptmann; Margriet van der Heiden-van der Loo; Otto Visser; Leontien C M Kremer; Cécile M Ronckers
Journal:  J Clin Oncol       Date:  2017-05-22       Impact factor: 44.544

3.  Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL.

Authors:  Brent Wood; David Wu; Beryl Crossley; Yunfeng Dai; David Williamson; Charles Gawad; Michael J Borowitz; Meenakshi Devidas; Kelly W Maloney; Eric Larsen; Naomi Winick; Elizabeth Raetz; William L Carroll; Stephen P Hunger; Mignon L Loh; Harlan Robins; Ilan Kirsch
Journal:  Blood       Date:  2017-12-28       Impact factor: 22.113

4.  Relative fitness of hematopoietic progenitors influences leukemia progression.

Authors:  C C Porter; D Baturin; R Choudhary; J DeGregori
Journal:  Leukemia       Date:  2011-02-18       Impact factor: 11.528

5.  Somatic and Germline TP53 Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors.

Authors:  Amy L Sherborne; Vincent Lavergne; Katharine Yu; Leah Lee; Philip R Davidson; Tali Mazor; Ivan V Smirnoff; Andrew E Horvai; Mignon Loh; Steven G DuBois; Robert E Goldsby; Joseph P Neglia; Sue Hammond; Leslie L Robison; Rosanna Wustrack; Joseph F Costello; Alice O Nakamura; Kevin M Shannon; Smita Bhatia; Jean L Nakamura
Journal:  Clin Cancer Res       Date:  2016-09-28       Impact factor: 12.531

6.  Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia.

Authors:  Jane E Churpek; Rafael Marquez; Barbara Neistadt; Kimberly Claussen; Ming K Lee; Matthew M Churpek; Dezheng Huo; Howard Weiner; Mekhala Bannerjee; Lucy A Godley; Michelle M Le Beau; Colin C Pritchard; Tom Walsh; Mary-Claire King; Olufunmilayo I Olopade; Richard A Larson
Journal:  Cancer       Date:  2015-12-07       Impact factor: 6.860

7.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

Authors:  D Malkin; F P Li; L C Strong; J F Fraumeni; C E Nelson; D H Kim; J Kassel; M A Gryka; F Z Bischoff; M A Tainsky
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

8.  Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study.

Authors:  Takaya Moriyama; Monika L Metzger; Gang Wu; Rina Nishii; Maoxiang Qian; Meenakshi Devidas; Wenjian Yang; Cheng Cheng; Xueyuan Cao; Emily Quinn; Susana Raimondi; Julie M Gastier-Foster; Elizabeth Raetz; Eric Larsen; Paul L Martin; W Paul Bowman; Naomi Winick; Yoshihiro Komada; Shuoguo Wang; Michael Edmonson; Heng Xu; Elaine Mardis; Robert Fulton; Ching-Hon Pui; Charles Mullighan; William E Evans; Jinghui Zhang; Stephen P Hunger; Mary V Relling; Kim E Nichols; Mignon L Loh; Jun J Yang
Journal:  Lancet Oncol       Date:  2015-10-28       Impact factor: 41.316

9.  Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.

Authors:  Terrence N Wong; Giridharan Ramsingh; Andrew L Young; Christopher A Miller; Waseem Touma; John S Welch; Tamara L Lamprecht; Dong Shen; Jasreet Hundal; Robert S Fulton; Sharon Heath; Jack D Baty; Jeffery M Klco; Li Ding; Elaine R Mardis; Peter Westervelt; John F DiPersio; Matthew J Walter; Timothy A Graubert; Timothy J Ley; Todd Druley; Daniel C Link; Richard K Wilson
Journal:  Nature       Date:  2014-12-08       Impact factor: 49.962

10.  Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia.

Authors:  David O'Connor; Amir Enshaei; Jack Bartram; Jeremy Hancock; Christine J Harrison; Rachael Hough; Sujith Samarasinghe; Claire Schwab; Ajay Vora; Rachel Wade; John Moppett; Anthony V Moorman; Nick Goulden
Journal:  J Clin Oncol       Date:  2017-11-13       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.